ISIS Pharmaceuticals (ISIS) Bullish Stance Reiterated at BMO Capital Post Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to ISIS Pharmaceuticals (ISIS) Bullish Stance Reiterated at BMO Capital Post Q1
May 6, 2014 3:22 PM EDT
Piper Jaffray upgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Neutral to Overweight.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $25.60 yesterday.
...
More
May 6, 2014 8:35 AM EDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q1 EPS of ($0.27), $0.04 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $35.12 million.
On a GAAP basis, Isis reported a loss from operations of $29.7 million for the three months ended March 31, 2014 compared to income from operations of $1.6 million for the same period in 2013. Isis maintained its strong cash position and ended the first quarter of 2014 with approximately $631 million in cash compared to $657 million at December 31, 2013.
"In the first quarter we have accomplished a number of... More
